Barclays raised the firm’s price target on Tenet Healthcare to $171 from $156 and keeps an Overweight rating on the shares. The company’s EBITDA guidance is now more realistic, but points to limited multiple expansion this year, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- Tenet Healthcare price target raised to $170 from $155 at Truist
- Tenet Healthcare price target raised to $175 from $130 at Raymond James
- Tenet Healthcare price target raised to $160 from $155 at Deutsche Bank
- Tenet Healthcare price target raised to $168 from $112 at Cantor Fitzgerald
- HCA Healthcare price target raised to $392 from $335 at Cantor Fitzgerald